0B68 Carabasi, Matthew - Thomas Jefferson University - Thomas Jefferson University
Dr. Carabasi

Matthew Carabasi, MD

Contact Dr. Carabasi

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation
  2. Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia
  3. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  4. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: How much progress has been made?
  5. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  6. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
  7. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
  8. Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen
  9. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
  10. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse
  11. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1]
  12. T cell depleted allogeneic PBSC transplantation using CD34+ cell selection
  13. NCCN Practice Guidelines for Acute Myelogenous Leukemia.
  14. A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants
  15. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
  16. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
  17. Resolution of Mirizzi's syndrome using endoscopic therapy
  18. Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia after Bone Marrow Transplantation: Separation of Graft-Versus-Leukemia Responses from Graft-Versus-Host Disease
  19. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response?
  20. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation